10x Genomics (TXG) Total Current Liabilities (2018 - 2026)

10x Genomics has reported Total Current Liabilities for 9 years, with the latest figure at $113.6 million in Q1 2026.

• Quarterly Total Current Liabilities rose 5.28% year-over-year to $113.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.6 million (up 5.28% YoY) and the FY2025 annual result came in at $153.5 million, up 30.45% from the prior year.
• Total Current Liabilities slipped to $113.6 million in Q1 2026 per TXG's latest filing, from $153.5 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $153.5 million in Q4 2025 and troughed at $94.4 million in Q1 2022.
• A 5-year average of $118.0 million and a median of $113.6 million in 2026 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities slipped 21.65% in 2022, then jumped 30.45% in 2025.
• Over 5 years, Total Current Liabilities stood at $131.0 million in 2022, then fell by 2.9% to $127.2 million in 2023, then dropped by 7.49% to $117.6 million in 2024, then soared by 30.45% to $153.5 million in 2025, then retreated by 25.97% to $113.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $113.6 million, $153.5 million, and $147.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.